Skip to main content
Signal8

Jaguar Health, Inc. (JAGX)

Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Jaguar Health, Inc. logo

Jaguar Health, Inc.

NASDAQ:JAGXHealthcare
-1.68%$0.3799
CLOSED
AH$0.3704-2.50%vs close
Mkt Cap$5.07M
EV-
Float–
O/S13.35M
VOL542K sh
$ Vol$196K
RVOL0.63×
Inst Own0.1%
Net Cash/Sh-
Dilution
Jaguar Health, Inc. logoNASDAQ:JAGXClosed$0.3799-1.68%

Jaguar Health, Inc. (JAGX) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 41 SEC filings.

Shelf registration
S-3 filed Oct 22, 2026, effective Nov 5, 2026
Source: 424B5 filed Nov 9, 2026
At-the-market (ATM) program
Yes, sales agreement dated Dec 10, 2021
Source: 424B5 filed Nov 9, 2026
Warrants outstanding
9 warrant series recorded as outstanding
Most recent offering
Offering, priced Sep 12, 2026
Source: 10-Q filed Nov 16, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro